Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $68558.0.

  • Lyra Therapeutics' Gains from Investment Securities changed N/A to $68558.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $68558.0, marking a year-over-year change of. This contributed to the annual value of $6.3 million for FY2024, which is 1058.81% up from last year.
  • As of Q3 2025, Lyra Therapeutics' Gains from Investment Securities stood at $68558.0.
  • Lyra Therapeutics' Gains from Investment Securities' 5-year high stood at $8.1 million during Q1 2024, with a 5-year trough of -$13.6 million in Q4 2024.
  • Its 5-year average for Gains from Investment Securities is $2.6 million, with a median of $4.2 million in 2022.
  • In the last 5 years, Lyra Therapeutics' Gains from Investment Securities surged by 2054887.62% in 2022 and then plummeted by 33760.15% in 2024.
  • Quarter analysis of 5 years shows Lyra Therapeutics' Gains from Investment Securities stood at $21000.0 in 2021, then skyrocketed by 20548.88% to $4.3 million in 2022, then soared by 31.68% to $5.7 million in 2023, then tumbled by 337.6% to -$13.6 million in 2024, then skyrocketed by 100.51% to $68558.0 in 2025.
  • Its Gains from Investment Securities was $68558.0 in Q3 2025, compared to $89959.0 in Q2 2025 and $4.5 million in Q1 2025.